November 2022

Abstract only

Renal cell carcinoma with venous thrombus: A retrospective single center surgical and oncological analysis
• C. Saitta,
• P. Diana,
• G. Lughezzani,
• ...
• A. Saita,
• G. Giorgio,
• N. Buffi
Published in issue: November 2022
S190
Impact of the COVID-19 pandemic on kidney cancer care in the Netherlands
• H. Yildirim,
• A.D. Bins,
• C. Van Den Hurk,
• P.J. Zondervan,
• K.K.H. Aben
Published in issue: November 2022
S191-S193
Sunitinib treatment modification in metastatic renal cell carcinoma – the impact of 2/1 dosing schedule and dose reduction in survival outcomes
• A.D.C. Valente,
• M. J. Costa,
• I. Nogueira Costa,
• ...
• S. Meireles,
• M. Barbosa,
• I. Augusto
Published in issue: November 2022
S194
A new nephrometry score developed for percutaneous microwave ablation of renal masses
• A. Uleri,
• E. Beatrici,
• P. Diana,
• ...
• P. Casale,
• V. Pedicini,
• N. Buffi
Published in issue: November 2022
S195-S196
Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN+PEMBRO) or sunitinib (SUN) in the CLEAR study
• M.H. Voss,
• T. Powles,
• B. Mcgregor,
• ...
• J. Mckenzie,
• K. Mody,
• R.J. Motzer
Published in issue: November 2022
S197-S198
Hereditary renal cell carcinoma surveillance protocols - a review and new surveillance protocol proposal
• M. Miranda,
• T.P. Leitão,
• C. Ferreira,
• ...
• A. Castro,
• F. Lopes,
• J. Palma Dos Reis
Published in issue: November 2022
S199
The impact of body mass index on clinical outcomes for patients receiving systemic anti-cancer therapies for advanced renal cell carcinoma
• J. Greene,
• Z. Wang,
• B. Harris,
• D. Dodwell,
• S. Lord
Published in issue: November 2022
S200-S201
Prognostic value of De Ritis (AST/ALT) ratio in patients undergoing nephrectomy for non-metastatic renal cell carcinoma: A propensity score-matching analysis
• D.S. Cho,
• H.J. Yoo,
• S.I. Kim,
• S.J. Kim
Published in issue: November 2022
S202-S205
A novel predictive model for primary antitumor immune response in advanced renal cell carcinoma
• M. Guer,
• A. Janitzky,
• M. Schostak
Published in issue: November 2022
S206
The impact of histology and type of energy used on oncological outcomes after local tumor ablation of small renal masses
• P. Piazza,
• L. Bianchi,
• S. Luzzago,
• ...
• O. De Cobelli,
• F. Montorsi,
• E. Brunocilla
Published in issue: November 2022
S207-S208
Prognostic significance of the preoperative platelet-lymphocyte ratio in nonmetastatic renal cell carcinoma
• K. Chaker,
• Y. Ouanes,
• W. Ben Chedly,
• ...
• A. Sellami,
• S. Ben Rhouma,
• Y. Nouira
Published in issue: November 2022
S209
Adherent perinephric fat as predictor of post-operative functional recovery after robot-assisted partial nephrectomy
• P. Diana,
• G. Garofano,
• A. Uleri,
• ...
• P. Casale,
• G. Guazzoni,
• N. Buffi
Published in issue: November 2022
S210
Pancreatic metastases of renal cell carcinoma: A single-centre case series
• M. Williamson,
• K. Herbert,
• A.S. Protheroe
Published in issue: November 2022
S211-S212
Thromboembolic disease in testicular germ cell tumors
• J. Albuquerque,
• D. N. Silva,
• L. Leal-Costa,
• ...
• J. Viegas Rato,
• J. Alberto Teixeira,
• J.L. Passos-Coelho
Published in issue: November 2022
S213
Treatment outcomes of men with stage 2 non-seminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: A systematic review
• A. Neuenschwander,
• C. Lonati,
• L. Antonelli,
• ...
• A. Lorch,
• M. Agostino,
• C.D. Fankhauser
Published in issue: November 2022
S214-S215
IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab
• T. Powles,
• Z. June Assaf,
• S. Mariathasan,
• ...
• C.A. Carter,
• J. Bellmunt,
• J.E. Gschwend
Published in issue: November 2022
S216-S217
ATM loss and therapeutic vulnerabilities in bladder cancer
• K. Mouw,
• Y. Zhou,
• E. Adib,
• ...
• R. Bekele,
• W. Anderson,
• Z. Szallasi
Published in issue: November 2022
S218
Trial In Progress: DISCUS: A randomized phase II study comparing 3 vs. 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer
• F.E. Jackson-Spence,
• T. Powles,
• Y.. Loriot,
• ...
• C. Ackerman,
• K. Mousa,
• E. Grande
Published in issue: November 2022
S219
Elaboration of an inmuno-nutritional prognostic index in patients with Muscle-Invasive Bladder (MIBC) Cancer radical prior to radical cystectomy
• J.C. Moreno Cortés,
• F Herranz-Amo,
• V. Bataller-Monfort,
• ...
• D. Subirá-Rios,
• M. Moralejo-Garate,
• C. Hernández-Fernández
Published in issue: November 2022
S220-S222
Is feasible to detect the PD-L1 expression by cytoinclusion technique in bladder cancer?
• L. Di Gianfrancesco,
• F. Pierconti
Published in issue: November 2022
S223
Histological spectrum and Immunohistochemistry based molecular subtyping of Variant Urothelial Carcinoma (VUC) and its prognostic implications
• I. Panda,
• N. Kakkar,
• R. Mohan,
• A. Sharma,
• S. Goyal,
• P. Rastogi
Published in issue: November 2022
S224
DNA mismatch repair testing in upper tract urothelial carcinoma patients - Is Universal Lynch Syndrome screening necessary?
• O.J.A. Figaroa,
• A.D. Bins,
• J. Baard
Published in issue: November 2022
S225
Evaluation of a cytology-molecular co-test in urine of patients with non-muscle invasive urothelial cancer
• P.J.V. Vlachostergios,
• C. Apostolopoulou,
• L. Mitrakas,
• ...
• M. Ioannou,
• M. Samara,
• E. Thodou
Published in issue: November 2022
S226
Bladder cancer detection in urine using DNA methylation markers: A prospective preclinical validation
• I.J. Beijert,
• A.E. Hentschel,
• J. Bosschieter,
• ...
• R.J.A. Van Moorselaar,
• R.D.M Steenbergen,
• J.A. Nieuwenhuijzen
Published in issue: November 2022
S227
The significance of FDG-PET/CT for detecting occult nodal metastases in patients with bladder cancer undergoing direct radical cystectomy
• L.G. Zuur,
• S.M.H. Einerhand,
• M.J. Wondergem,
• T.N. Boellaard,
• B.W.G. Van Rhijn,
• L.S. Mertens
Published in issue: November 2022
S228-S229
Expression of Nectin-4 in variant histologies of bladder cancer – implications for perioperative systemic therapy
• S. Rodler,
• J. Casuscelli,
• B. Schlenker,
• ...
• S. Ledderose,
• C. Stief,
• L. Eismann
Published in issue: November 2022
S230
Robot-assisted, laparoscopic, and open radical cystectomy: Surgical data of 1400 patients from The Italian Radical Cystectomy Registry (RIC) on intraoperative outcomes
• A. Porreca,
• L. Di Gianfrancesco,
• W. Artibani,
• ...
• D. D’Agostino,
• P. Corsi,
• A. Crestani
Published in issue: November 2022
S231-S232
Optimized adaptive radiotherapy with plan library for muscle invasive bladder cancer
• Y.Y. Jo,
• J.W. Yea,
• J. Park,
• J.W. Park
Published in issue: November 2022
S233
Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy
• F. Albert,
• A. Antoniewicz,
• T. Grantzow,
• ...
• H. Lindhofer,
• M. Kriegmair,
• R. Oberneder
Published in issue: November 2022
S234-S235
Impact of maximal transurethral resection of bladder tumor before neoadjuvant chemotherapy for muscle-invasive bladder cancer
• D.H. Marmolejo Castaneda,
• R. Morales-Barrera,
• C. Suarez,
• ...
• I. De Torres,
• C. Raventos,
• J. Carles
Published in issue: November 2022
S236
Electromotive drug administration of mitomycin C versus Bacillus de Calmette Guérin as intravesical adjuvant treatment of non-muscle invasive bladder cancer
• Y. Yáñez Castillo,
• M.T. Melgarejo Segura,
• A. Morales Martínez,
• M. Pareja Vílchez,
• M. Arrabal Polo,
• M. Arrabal Martín
Published in issue: November 2022
S237
Adjuvant treatment of intermediate- and high-risk non-muscle invasive bladder cancer with device-assisted chemotherapy instillations
• Y. Yáñez Castillo,
• M.T. Melgarejo Segura,
• A. Morales Martínez,
• M. Pareja Vílchez,
• M.Á. Arrabal Polo,
• M. Arrabal Martín
Published in issue: November 2022
S238
Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase 3 CheckMate 274 trial
• A. Necchi,
• D.F. Bajorin,
• Y. Tomita,
• ...
• A. Apfel,
• K. Ünsal-Kaçmaz,
• M.D. Galsky
Published in issue: November 2022
S239-S240
Role of restaging transurethral resection of bladder tumor in non-muscle invasive urothelial carcinoma: An overtreatment?
• U.P. Singh,
• N. Mishra,
• A. Misra,
• A. Srivastava
Published in issue: November 2022
S241
Phase 1 trial of Hypofractionated radiotherapy and Pembrolizumab in the treatment of locally advanced or metastatic bladder cancer: Results of dose escalation phase of the PLUMMB trial (NCT02560636)
• R.A. Huddart,
• K. Jones,
• G. Bucinskaite,
• ...
• E. Greenlay,
• L. Potts,
• S. Hafeez
Published in issue: November 2022
S242-S243
Systemic inflammatory index as a predictor of BCG-refractory non-muscle invasive bladder cancer
• J. Monteiro,
• A.C. Caetano,
• C.A. Costa,
• ...
• P. Madeira,
• N. Bonito,
• G. Sousa
Published in issue: November 2022
S244
Avelumab as maintenance treatment in advanced urothelial cancer in the Portuguese population: A multicentric registry analysis
• J. Gramaça,
• C. Trabulo,
• L. Alves,
• ...
• A. Baptista,
• C. Pinto,
• I.M. Matos Pina
Published in issue: November 2022
S245-S246
Role of neutrophil-to-lymphocytes ratio in predicting non-complete response at 3 months evaluation after BCG induction in non-muscle invasive bladder cancer
• D. Chung,
• J. Lee,
• S. Yoo,
• ...
• M.C. Cho,
• H. Son,
• H. Jeong
Published in issue: November 2022
S247
Follow-up after kidney sparing surgery in upper tract urothelial carcinoma, an overview of 10 year contemporary data; Do we need to adjust current follow up protocol?
• O.J.A. Figaroa,
• N. Hendriks,
• G.M. Kamphuis,
• A.D. Bins,
• H.P. Beerlage,
• J. Baard
Published in issue: November 2022
S248-S249
Prognostic value of vascular endothelial growth factor and vascular cell adhesion molecule-1 in bladder carcinoma
• K. Mori,
• V. Schuettfort,
• T. Yanagisawa,
• ...
• H. Mostafaei,
• T. Kimura,
• S.F. Shariat
Published in issue: November 2022
S250
Stage dependent survival in patients treated with NAC and RC: Implications for patient selection and adjuvant therapy
• D. D’Andrea,
• S.F. Shariat,
• F. Soria,
• ...
• A. Mari,
• M. Moschini
• On behalf of the European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group
Published in issue: November 2022
S251
Stage matched head-to-head comparison between urachal carcinoma and urothelial bladder cancer: TNM-stage based analysis from a national multicenter database
• S.H. Song,
• J.H. Kim,
• J.H. Nam,
• ...
• S. Hong,
• J.J. Oh
• Korean Urologic Oncology Group - Bladder Cancer Research Society
Published in issue: November 2022
S252-S254
Validation of a GATA2 methylation and FGFR3 mutation assay to predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer
• M. Olislagers,
• F.C. De Jong,
• V.M.J. Van Etten,
• T.W. Kan,
• T.C.M. Zuiverloon
Published in issue: November 2022
S255-S256
Small Cell Carcinoma (SmCC) of the bladder, treated in one Athenian oncologic center
• N. Alevizopoulos,
• D.A Alexandris,
• V.O Oreopoulos,
• ...
• C.G Gakiopoulou,
• S.T Theocharis,
• M.V Vaslamatzis
Published in issue: November 2022
S257
The impact of radical cystectomy on renal function: Identification of risk factors for development of chronic kidney disease
• C. Minguez Ojeda,
• A. Artiles Medina,
• A. Sanchez Gonzalez,
• ...
• J.D. Subiela Hernandez,
• M.A. Jimenez Cidre,
• F.J. Burgos Revilla
Published in issue: November 2022
S258-S259
Outcomes of patients with metastatic urothelial cancer who have received previous first line therapy
• F.E. Jackson-Spence,
• L. Furtado O’Mahony,
• C. Toms,
• ...
• J. Choy,
• B.E. Szabados,
• T. Powles
Published in issue: November 2022
S260
Urostoma APPtimize: Improving quality of life of patients having an urostomy by offering personalised and timed guidance in a patient-centred mobile application
• N. van Ginkel,
• S.L. Van Der Storm,
• J.A. Witjes,
• ...
• A.N. Vis,
• J.R. Oddens,
• M.P. Schijven
Published in issue: November 2022
S261-S262
Tumour size in adrenal tumours: Its importance in the indication of adrenalectomy and surgical outcomes. Single-centre experience
• C. Minguez Ojeda,
• M. Araujo Castro,
• A. Tagalos Muñoz,
• ...
• V. Diez Nicolas,
• V. Gomez Dos Santos,
• F.J. Burgos Revilla
Published in issue: November 2022
S263-S264
COVID-19 pandemic impact in bladder cancer treatment and features
• J.A. Pereira,
• J. Pedroso Lima,
• M. Lopes,
• ...
• L.B. Sousa,
• V. Sousa,
• A. Figueiredo
Published in issue: November 2022
S265
Practical approach and surgical outcome to treatment rectourinary fistula in male cancer patients
• L. Tryfonyuk,
• T. Shcheglovska,
• V. Milinevsky,
• ...
• J. Bernal,
• O. Yatsyna,
• F.E. Martins
Published in issue: November 2022
S266